SCHEMBL24310325

SCHEMBL24310325

C/C(=C/C(C)C)c1ccccc1-c1cc(Oc2ccc(N3CCN(C)CC3)cc2)nc(NSc2cnn(C)c2)n1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 2/20 0.32
▸ FGFR1 P11362 2/20 0.31
▸ SRC P12931 2/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ MAP3K7 O43318 1/20 0.31
▸ ALK Q9UM73 1/20 0.31
▸ CDK4 P11802 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ GSK3B P49841 1/20 0.31
▸ MET P08581 2/20 0.31
▸ EGFR P00533 3/20 0.30
▸ KDR P35968 1/20 0.30
▸ KDM1A O60341 3/20 0.30
▸ IRAK4 Q9NWZ3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566598 0.85 HTR2C (0.34) MAP4K1FGFR1SRCNPC1TP53
SCHEMBL24310328 0.85 HTR2C (0.34) MAP4K1FGFR1SRCNPC1TP53
SCHEMBL24309807 0.84 CDK4 (0.33) MAP4K1FGFR1SRCNPC1TP53
SCHEMBL24310306 0.83 CDK4 (0.34) MAP4K1ALKCDK4CDK2GSK3B
SCHEMBL24310318 0.82 MAP4K1 (0.42) MAP4K1NPC1MAPTMAPK1RAB9A
SCHEMBL24310522 0.82 MAP4K1 (0.31) MAP4K1CDK4CDK2GSK3BKDM1A
SCHEMBL24310329 0.81 MET (0.32) MAP4K1CDK4CDK2GSK3BMET
SCHEMBL24310517 0.81 CDK4 (0.33) MAP4K1CDK4CDK2GSK3B
SCHEMBL24309676 0.77 FLT3 (0.38) MAP4K1TSHRKMT2ACDK4CDK2
SCHEMBL24310524 0.77 BRD4 (0.37) METEGFRIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback